Volume Spike Investor

VIVUS Inc. (NASDAQ: VVUS) is popping up hard this morning as the company may soon have a new erectile dysfunction drug on the market if the test results lead to an FDA approval.  It announced positive results in a phase 3 pivotal study evaluating the safety and efficacy of avanafil for the treatment of erectile dysfunction with faster benefits and low side-effects.  Shares are up over 13% at $9.75 on over 700,000 shares as of 8:09 AM EST.  The 52-week trading range is $2.72 to $12.88 and the average daily volume now is 5.4 million shares.

JON OGG